Bionics Institute
Leah Wallenaffer is an experienced finance and payroll professional with a robust background in accounting and financial management. Currently serving as a Finance & Payroll Officer at Bionics Institute since March 2016, Leah has previously held positions in various roles, including Accounts Payable at SoilWorx and Bookkeeper at BJS Building. Leah's career in finance began as a Purchasing & Payables Clerk at Peter Rowland from November 2000 to August 2009. Additionally, Leah holds a Diploma in Children’s Services from Victoria University, attained between 1998 and 2000.
This person is not in the org chart
Bionics Institute
The Bionics Institute is an internationally recognised, independent medical research institute that solves medical challenges with technology. We lead the world in the research and development of innovative medical devices and therapies to improve human health. Our multidisciplinary team is comprised of world-class scientists, engineers and researchers, and our laboratories are located in St Vincent’s Hospital Melbourne, close to our clinical collaborators. Together we transform the lives of people with a range of conditions, including Alzheimer’s disease, hearing impairment, vision loss, Crohnʼs disease, Parkinsonʼs disease, stroke, arthritis, incontinence and diabetes. The Bionics Institute has an impressive track record of translating medical device concepts into clinical reality dating back to 1986 when it was founded by Professor Graeme Clark, leader of the team that created Australiaʼs cochlear implant. Since then, Bionics Institute researchers have developed: • Australiaʼs first-generation bionic eye prototype implanted in clinical trials in 2018. - The epilepsy seizure monitoring device Minder™, commercialised through Epi-Minder Pty Ltd. - An adaptive deep brain stimulation system for Parkinsonʼs disease, commercialised through Deep Brain Stimulation Technologies Pty Ltd. - An innovative vagus nerve stimulation device to treat inflammatory bowel disease, which is moving into clinical trials and also being adapted to treat rheumatoid arthritis and diabetes. - Novel drug delivery methods for hearing loss; new diagnostic tools for improved diagnosis of infant hearing. Growth into new areas will build on our expertise in medical device development and a recent expansion of our world-class facilities to include the end-to-end medical device prototype manufacturing facility, Neo-Bionica.